Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1826 • 2017 ACR/ARHP Annual Meeting
Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) Related Remission: 2-Year Results from a Phase 3 Study
Laura C Coates¹, Dafna D Gladman², Peter Nash³, Oliver FitzGerald⁴, Arthur Kavanaugh⁵, Lawrence Rasouliyan⁶, Luminita Pricop⁷, Kevin Ding⁷ and Corine Gaillez⁸, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Toronto Western Hospital, Toronto, ON, Canada, ³University of Queensland, Brisbane, Australia, ⁴St Vincent's University Hospital, Dublin, Ireland, ⁵UC San Diego School of Medicine, La Jolla, CA, ⁶RTI Health Solutions, Barcelona, Spain, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Psoriatic arthritis (PsA) disease activity score (PASDAS) assessing multiple facets of PsA was demonstrated to distinguish treatment effect, perform better in statistical terms than…
Abstract Number: 619 • 2017 ACR/ARHP Annual Meeting
Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
Peter Nash¹, Laura C Coates², Roy Fleischmann³, Kim Papp⁴, Juan J. Gomez-Reino⁵, Keith S Kanik⁶, Cunshan Wang⁶, Joseph Wu⁶, Thijs Hendrikx⁷ and William C Ports⁶, ¹Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁴Probity Medical Research and K. Papp Clinical Research Inc, Waterloo, ON, Canada, ⁵Fundacion Ramon Dominguez, Hospital Clinico Universitario, Santiago de Compostela, Spain, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA). We examined tofacitinib efficacy in patients (pts) with active…
Abstract Number: 1829 • 2017 ACR/ARHP Annual Meeting
Patterns and Predictors of Progression of Sacroiliitis in Psoriatic Arthritis and Its Relationship with Human Leukocyte Antigen (HLA) Alleles. Results from the Toronto Cohort
Musaab Elmamoun¹, Justine (Yang) Ye², Richard J. Cook³, Vinod Chandran⁴ and Dafna D Gladman⁵, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Medicine, Krembil Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is clinically heterogeneous, with broad phenotypes of musculoskeletal (MSK) involvement including peripheral arthritis, enthesitis, dactylitis, and axial involvement. Sacroiliitis (SI) in…
Abstract Number: 620 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open‑Label, Long-Term Extension Study
Peter Nash¹, Laura C Coates², Alan J. Kivitz³, Philip J Mease⁴, Dafna D Gladman⁵, Jose A Covarrubias-Cobos⁶, Dona Fleishaker⁷, Cunshan Wang⁷, Elizabeth Kudlacz⁷, Sujatha Menon⁷, Thijs Hendrikx⁸ and Keith S Kanik⁷, ¹Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Unidad Reumatologica Las Americas S.C.P, Yucatán, Mexico, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA). Interim data up to January 2017 (database not locked) report the…
Abstract Number: 1874 • 2017 ACR/ARHP Annual Meeting
Development of an Ultrasonographic Enthesitis Score for Psoriatic Arthritis Patients
Stephanie Tom^1,2, Yujie Zhong³, Richard J. Cook⁴, Sibel Z. Aydin^5,6, Gurjit S. Kaeley⁷ and Lihi Eder^8,9, ¹Women's College Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵The Ottawa Hospital, Ottawa, ON, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷University of Florida, Ponte Vedra Beach, FL, ⁸Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ⁹Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Enthesitis affects approximately a third of patients with psoriatic arthritis (PsA) and is often considered the earliest site of inflammation. The accuracy of clinical…
Abstract Number: 623 • 2017 ACR/ARHP Annual Meeting
Tofacitinib Improves Composite Endpoint Measures of Disease in Patients with Psoriatic Arthritis
Philip S. Helliwell¹, Laura C Coates¹, Oliver FitzGerald², Peter Nash³, Enrique R Soriano⁴, M. Elaine Husni⁵, Ming-Ann Hsu⁶, Keith S Kanik⁶, Thijs Hendrikx⁷, Joseph Wu⁶ and Elizabeth Kudlacz⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²ASRI, Dublin, Ireland, Dublin, Ireland, ³Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Cleveland Clinic Lerner Research Institute, Cleveland, OH, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). PsA is a heterogeneous disease and composite endpoints…
Abstract Number: 2030 • 2017 ACR/ARHP Annual Meeting
Patient Motivation in Inflammatory Arthritis: The Use of Ultrasound-Guided Patient Education to Endorse Medication Adherence and Facilitate Cost-Effective Targeted Management
Yasser M. El Miedany^1,2, Maha El Gaafary³, Nadia El Aroussy¹, Sally Youssef⁴ and Deborah Palmer⁵, ¹Rheumatology and Rehabilitation, Ain Shams University, Cairo, Egypt, ²Rheumatology, Darent Valley Hospital, Dartford, United Kingdom, ³Community, Environmental and Occupational Medicine, Ain Shams University, Abbassia, Egypt, ⁴Rheumatology & Rehabilitation, Ain Shams University, Cairo, Egypt, ⁵Rheumatology, North Middlesex University Hospital, London, United Kingdom
Background/Purpose: To assess the value of sharing the real-time ultrasound (US) images of the inflamed joints/ tendons with inflammatory arthritis patients and its impact on:…
Abstract Number: 179 • 2017 ACR/ARHP Annual Meeting
Mass Spectrometry Imaging of Synovium: A Novel Approach to Classify the Rheumatoid and Psoriatic Arthritis Patients
Beatriz Rocha^1,2, Berta Cillero-Pastor³, Gert Eijkel³, Lennart R. Huizing³, Cristina Ruiz-Romero^1,4, Andrea Cuervo^5,6, Ron M A Heeren³, Juan D. Cañete^5,6 and Francisco J Blanco^1,6, ¹Rheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC - Hospital Universitario de A Coruña, A Coruña, Spain, A Coruña, Spain, ²The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, The Netherlands, Masstricht, Netherlands, ³The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, The Netherlands, Maastricht, Netherlands, ⁴CIBER-BBN Instituto de Salud Carlos III, INIBIC-CHUAC, A Coruña, Spain., A Coruña, Spain, ⁵Arthritis Unit, Rheumatology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁶RIER-RED de Inflamación y Enfermedades Reumáticas, INIBIC-CHUAC, A Coruña, Spain, A Coruña, Spain
Background/Purpose: Psoriatic arthritis (PsA) and Rheumatoid arthritis (RA) are immune-mediated chronic inflammatory diseases. Synovial membrane is the initial site of inflammation in PsA and RA…
Abstract Number: 627 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Apremilast through 104 Weeks in Subjects with Moderate to Severe Psoriasis Randomized to Placebo, Apremilast, or Etanercept Who Continued on or Switched to Apremilast after Week 16 in a Phase 3b Study
Kristian Reich¹, Mark Goodfield², Lawrence Green³, Kristine Nograles⁴, Rongdean Chen⁴, Eugenia Levi⁴ and Richard G.B. Langley⁵, ¹Dermatologikum Hamburg, Hamburg, Germany, ²Leeds General Infirmary, Leeds, United Kingdom, ³George Washington University School of Medicine, Washington, DC, WA, ⁴Celgene Corporation, Summit, NJ, ⁵Dalhousie University, Halifax, NS, Canada
Background/Purpose: Many subjects (sbj) with chronic plaque psoriasis exhibit nail and scalp involvement that can markedly affect quality of life and be difficult to treat.…
Abstract Number: 2438 • 2017 ACR/ARHP Annual Meeting
Open Label Transitioning from Originator Etanercept to Biosimilar SB4 Compared to Continuing Treatment with Originator Etanercept in a Historical Cohort in Rheumatic Diseases in Daily Practice
L. Tweehuysen¹, V.J.B. Huiskes², B.J.F. Van den Bemt (PharmD, PhD)³, S. Teerenstra⁴, F.H.J. van den Hoogen⁵, C.H.M. van den Ende⁵ and A.A. Den Broeder⁵, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands, ³Pharmacy, Sint Maartenskliniek and Radboudumc, Nijmegen, Netherlands, ⁴Biostatistics, Radboudumc, Nijmegen, Netherlands, ⁵Rheumatology, Sint Maartenskliniek and Radboudumc, Nijmegen, Netherlands
Background/Purpose: Blinded transitioning from originator infliximab (INX) to biosimilar CT-P13 was not inferior to continuing INX treatment.1 Open label mandatory transitioning resulted in a slightly…
Abstract Number: 10L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial
Dafna D Gladman¹, William Rigby², Valderilio F Azevedo³, Frank Behrens⁴, Ricardo Blanco⁵, Andrzej Kaszuba⁶, Elizabeth Kudlacz⁷, Cunshan Wang⁷, Sujatha Menon⁷, Thijs Hendrikx⁸ and Keith S Kanik⁷, ¹University of Toronto, Toronto, ON, Canada, ²Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, ³Federal University of Parana and Edumed Health Research Center and Biotech, Curitiba, Brazil, ⁴Johann Wolfgang Goethe University, Frankfurt, Germany, ⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁶Specialstyczne Gabinety Lerkarskie "DERMED", Lodz, Poland, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of PsA. In this first study of tofacitinib in patients (pts) with active…
Abstract Number: 1326 • 2016 ACR/ARHP Annual Meeting
Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthropathy, Following Lyme Disease
Sheila Arvikar¹, Jameson Crowley¹, Katherine Sulka² and Allen C. Steere³, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Charlestown, MA, ²Rheumatology Allergy and Immunology, Massachusetts General Hospital, Charlestown, MA, ³Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Lyme arthritis (LA) usually responds to antibiotic therapy, though immune-mediated synovitis may persist after antibiotic treatment, usually confined to a previously infected joint,…
Abstract Number: 1729 • 2016 ACR/ARHP Annual Meeting
Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Infliximab Using a Matching-Adjusted Indirect Comparison
Vibeke Strand¹, Philip J Mease², Iain B McInnes³, Peter Nash⁴, Howard Thom⁵, Matthias Hunger⁶, Kunal Gandhi⁷, Shephard Mpofu⁸ and Steffen Jugl⁸, ¹Stanford University School of Medicine, Palo Alto, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Department of Medicine, University of Queensland, Brisbane, QLD, Australia, ⁵University of Bristol, Bristol, United Kingdom, ⁶MAPI Group, Munich, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) and infliximab (INF) are approved for the treatment of active PsA in adults with an inadequate response to conventional DMARDs. There are…
Abstract Number: 1422 • 2016 ACR/ARHP Annual Meeting
Identifying Generic and Specific Patients’ Perspectives on Disease- and Treatment-Related Issues in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: A Qualitative Concept Mapping Study
Tanja Schjødt Jørgensen¹, Louise Klokker¹, Henrik Gudbergsen², Simon Francis Thomsen³, Robin Christensen⁴, Henning Bliddal¹ and Lars Erik Kristensen¹, ¹The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg,, Copenhagen, Denmark, ³Department of Dermatology, Bispebjerg Hospital & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
Identifying generic and specific patients’ perspectives on disease- and treatment-related issues in rheumatoid arthritis, psoriatic arthritis, and psoriasis: a qualitative concept mapping studyT.S. Jørgensen1, L.…
Abstract Number: 1731 • 2016 ACR/ARHP Annual Meeting
Disease Burden and Impact of Certolizumab Pegol Treatment on Workplace and Household Productivity Across Working Age Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis Patients
Arthur F. Kavanaugh¹, Philip J. Mease², Oana Purcaru³ and Désirée van der Heijde⁴, ¹Division of Rheumatology, Allergy, and Immunology, UC San Diego School of Medicine, La Jolla, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³208 Bath Road, UCB Pharma, Slough, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), can impact…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].